Proteinase K Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

The Proteinase K Market is Segmented by Form (Powder and Liquid), Therapeutic Area (Infectious Diseases, Diabetes, Oncology, Cardiology, and Other Therapeutic Areas), and Geography (North America, Europe, Asia-Pacific, and Rest of the World). The report offers the value (in USD million) for the above segments.

Proteinase K Industry Overview

Proteinase K Market Overview
Study Period: 2018 - 2028
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 3 %

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Proteinase K Market Analysis

The proteinase K market is expected to register a CAGR of nearly 3% during the forecast period.

COVID-19 had a significant impact on the growth of the market. Proteinase K had great potential in the detection of COVID-19, which contributed to providing growth avenues to the market. As per a study titled, “Rapid, convenient and efficient kit-independent detection of SARS-CoV-2 RNA”, published in December 2020, simple proteinase K treatment and repetitive heating steps with a sensitivity of 94.6% were compared with kit-based isolation methods. It was found that the proteinase K method can be considered a convenient and efficient method for the extraction of SARS-CoV-2 RNA. Thus, the COVID-19 outbreak contributed to rising demand for the proteinase K market during the pandemic period.

The rising burden of chronic disorders and infectious diseases and the growing applications of diagnostic techniques and their associated enzymes for IVD​ are among key trends that are expected to trigger market growth. The article titled "A nationwide population-based study of incidence and mortality of lung cancer in idiopathic pulmonary fibrosis " published in Nature Journal in January 2021 mentioned that the prevalence of lung cancer in idiopathic pulmonary fibrosis cases was 6.4%. The article also mentioned that of the 464 patients in the IPF with Lung Cancer group, 54.7% were diagnosed with idiopathic pulmonary fibrosis before lung cancer 27.4% has a simultaneous diagnosis of idiopathic pulmonary fibrosis and lung cancer and 17.9% were diagnosed with lung cancer idiopathic pulmonary fibrosis. Such prevalence of various chronic diseases is also expected to drive the demand for the proteinase K market, thereby contributing to the growth of the market.

Chronic diseases are the most prevalent health condition globally. Chronic diseases include cancer, diabetes, hypertension, stroke, heart disease, respiratory diseases, arthritis, and obesity, which lead to hospitalization, long-term disability, reduced quality of life, and even death.​ According to GLOBOCAN 2020, the 5-year prevalence of cancer was reported to be around 50,550,287 worldwide, and about 9,958,133 deaths due to cancer were recorded globally. The rising prevalence of cancer has led to an increase in next-generation sequencing and polymerase chain reaction applications, thereby contributing to the growth of the market during the forecast period.

Furthermore, the increasing research and development activities and investments by research institutes and pharmaceutical and biopharmaceutical companies in innovation help the market to grow. However, the availability of new sophisticated technologies for DNA purification may hamper the growth of the proteinase K market over the forecast period.

Proteinase K Industry Segments

As per the scope, proteinase K is known as a proteolytic enzyme (serine protease) that is used to digest proteins and remove contamination from nucleic acid preparation. Proteinase K in nucleic acid preparations rapidly inactivates DNAases and RNases that otherwise degrade DNA and RNA during the course of purification. Proteinase K is used for the destruction of proteins in cell lysates such as tissue, and cell culture cells, and for the release of nucleic acids. It is also widely used in DNA extraction for digesting contaminated proteins and protects nucleic acid from nuclease attack. The proteinase K market is segmented by form (powder and liquid), therapeutic area (infectious diseases, diabetes, oncology, cardiology, and other therapeutic areas), and geography (North America, Europe, Asia-Pacific, and Rest of the World). The report offers the value (in USD million) for the above segments.

By Form
Powder
Liquid
By Therapeutic Area
Infectious Diseases
Diabetes
Oncology
Cardiology
Other Therapeutic Areas
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Rest of the World

Report scope can be customized per your requirements. Click here.

Proteinase K Market Trends

This section covers the major market trends shaping the Proteinase K Market according to our research experts:

The Infectious Diseases Segment is Expected to Dominate the Market Over the Forecast Period

The infectious diseases segment is found to dominate the proteinase K market which has been attributed to the increasing prevalence of infectious diseases and the wide applicability of proteinase K in the diagnosis of various infectious diseases.

There is also a rising number of infectious diseases that have helped in boosting the overall market growth. According to the study published in Clinical Infectious Diseases, titled "Re-emergence of Invasive Pneumococcal Disease (IPD) in Germany during the Spring and Summer of 2021" in February 2022, in April 2021, IPD levels in children aged 0 to 4 years old began to rebound to baseline levels, and by June 2021, they had surpassed them. IPD cases increased beyond baseline values in children 5 to 14, adults 15-34, and people 80 years and older beginning in July 2021, with increases, also beginning in Spring 2021. Proteinase K is used to extract genetic material from the target sample and is used in the diagnosis of pneumonia disease. Thus the incidence of pneumonia cases is expected to contribute to the growth of the studied segment.

The report “HIV testing, new HIV diagnoses, outcomes and quality of care for people accessing HIV services: 2021 report” published by the United Kingdom Health Security Agency in December 2021, stated that in 2020, an estimated 97,740 people were living with HIV in England and an estimated 4,660 in 2020 were unaware of their infection indicating that diagnostic services are not provided to a larger extent of the people. Therefore, the market in the country has great potential to grow.

The article titled " Prevalence, incidence, and seroconversion of HIV and syphilis infections among pregnant women of South Africa "published in August 2021 mentioned that the prevalence of HIV and Syphilis were 44.3% and 3.8% respectively. Such an incidence in the prevalence of HIV and syphilis among the South African population led to the high demand for proteinase K, thereby contributing to the growth of the market.

Moreover, several studies show that incubation of DNA for the hepatitis B virus with proteinase K results in efficient DNA isolation. The DNA yield from this proteinase K is being increased by 5 times compared to standard procedures that do not require proteinase K. Thus, the wide applicability of proteinase K in the diagnosis of several infectious diseases is a key factor that helps the market grow.

Estimated Number of Tuberculosis Cases,

North America is Expected to Dominate the Proteinase K Market Over the Forecast Period

North America is found registering high growth in the region due to the increasing number of cancer and infectious diseases and growing next-generation sequencing and polymerase chain reaction applications that are found boosting the market growth in the region. This is expected to drive the demand for proteinase K required in NGS and PCR techniques.

Moreover, with the emergence of COVID-19, the use of proteinase K registered increased, and therefore, new products were developed, which impacted the market positively. For instance, in May 2020, Zymo research received an Emergency Use Authorization by the United States Food and Drug Administration for “Quick SARS-CoV-2 rRT-PCR Kit” that includes “Proteinase K w/ Storage Buffer set”. Such product approvals are expected to boost the demand for proteinase K.

According to the United States' National Center for Health Statistics, chronic diseases affect approximately 133 million Americans, representing more than 40% of the total population of the country, and by 2020, it is projected to grow to an estimated 157 million, with 81 million having multiple conditions.

Similar to this, the Centerf for Disease Control and Prevention (CDC) reported in May 2022 that 30,635 people in the United States and dependent territories acquired an HIV diagnosis in 2020.

Also, the increasing funding from the United States government for supporting healthcare is an attributing factor to the growth of the market in the United States. For instance, the Congressional Budget Office,2021, published that in the past few decades, federal funding for the National Institute of Health (NIH) has totaled over USD 700 billion. Therefore, all these factors are found creating high growth opportunities for proteinase K in the North American region.

Proteinase K Market- Growth Rate By Region

Proteinase K Market Competitor Analysis

The proteinase K market is moderately competitive and few of the major players are currently dominating the market. Some of the companies currently dominating the market are Merck KGaA, F. Hoffmann-La Roche Ltd, Advanced Enzyme Technologies, Thermo Fisher Scientific, QIAGEN, G Biosciences, Dyadic International, Amicogen, A and A biotechnology and others. 

Proteinase K Market Top Players

  1. Merck KGaA

  2. Thermo Fisher Scientific

  3. QIAGEN

  4. A and A Biotechnology

  5. G Biosciences

*Disclaimer: Major Players sorted in no particular order

proteinase k - mc.jpg

Proteinase K Market Recent Developments

  • In September 2022, ThermoFisher Scientific opened a USD 160 million, 85,000 square-foot facility in Chelmsford, MA, 30 miles north of its headquarters in Waltham.
  • In August 2021, Amicogen invested a total of USD 43027.03 Million to build a new factory. The new factory will be established on a site of 4,504 Square meters for the expansion of the company's biopharmaceutical production.

Proteinase K Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Burden of Chronic and Infectious Diseases

      2. 4.2.2 Growing Applications of Diagnostic Techniques and their Associated Enzymes for IVD​

    3. 4.3 Market Restraints

      1. 4.3.1 Availability of New Sophisticated Technologies for DNA Purification

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value – USD million)

    1. 5.1 By Form

      1. 5.1.1 Powder

      2. 5.1.2 Liquid

    2. 5.2 By Therapeutic Area

      1. 5.2.1 Infectious Diseases

      2. 5.2.2 Diabetes

      3. 5.2.3 Oncology

      4. 5.2.4 Cardiology

      5. 5.2.5 Other Therapeutic Areas

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Rest of the World

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Merck KGaA

      2. 6.1.2 F. Hoffmann-La Roche Ltd

      3. 6.1.3 Advanced Enzymes Technologies

      4. 6.1.4 Thermo Fisher Scientific

      5. 6.1.5 Dyadic International

      6. 6.1.6 QIAGEN

      7. 6.1.7 Cell Signalling Technology Inc.

      8. 6.1.8 Danaher Corporation (Leica Biosystems)

      9. 6.1.9 Geno Technology Inc. (G Bioscience)​

      10. 6.1.10 Amicogen

      11. 6.1.11 A & A Biotechnology

      12. 6.1.12 bioWORLD

      13. 6.1.13 New England Biolabs

      14. 6.1.14 Promega Corporation

      15. 6.1.15 Avantor

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You can also purchase parts of this report. Do you want to check out a section wise price list?

Proteinase K Market Research FAQs

The Global Proteinase K Market is studied from 2018 - 2028.

The Global Proteinase K Market is growing at a CAGR of 3% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2018 - 2028.

North America holds highest share in 2021.

Merck KGaA, Thermo Fisher Scientific, QIAGEN, A and A Biotechnology , G Biosciences are the major companies operating in Global Proteinase K Market .

Global Proteinase K Industry Reports

In-depth industry statistics and market share insights of the Global Proteinase K Market sector for 2020, 2021, and 2022. The Global Proteinase K Market research report provides a comprehensive outlook of the market size and an industry growth forecast for 2023 to 2028. Available to download is a free sample file of the Global Proteinase K Market report PDF.

close-icon
80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!